|
|
 | | | | | | | Imipramine and paroxetine: bipolar depression 1
Authors: Nemeroff et al.
Title: Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression.
Reference: Am J Psychiatry 2001;158:906-12.
Purpose: To compare the efficacy and safety of paroxetine and imipramine with placebo in the treatment of bipolar depression in patients stabilized on lithium.
Study design: Randomized, double-blinded study.
Follow up: 10 weeks.
Patients: 117 patients (35 paroxetine, 39 imipramine, and 43 placebo).
Treatment: paroxetine 20–50 mg/day, imipramine 50–300 mg/day, or placebo.
Results: Imipramine and paroxetine were found to be superior to placebo as add-on therapy, but only in patients whose serum lithium level was <0.8 mEq/L. In patients with a serum lithium level >0.8 mEq/L, there were no differences among the groups.
| | | |
|
